|
Match
|
Document |
Document Title |
|
|
US20110293723 |
SYNTHETIC NANOCARRIER COMBINATION VACCINES
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are... |
|
|
US20140193416 |
OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICLE POLYSACCARIDE PS-I, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS VACCINES AND DIAGNOSTIC TOOLS
The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide... |
|
|
US20140004150 |
Vaccine Injection, Preparation Method and Use Thereof
The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal... |
|
|
US20140341974 |
Liposomal Vaccine Adjuvants and Methods of Making and Using Same
A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl... |
|
|
US20110135685 |
Edible Vaccines Expressed in Soybeans
The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines... |
|
|
US20120003277 |
NANOEMULSION VACCINES
The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more... |
|
|
US20110076305 |
EXTRACELLULAR MATRIX MATERIALS AS VACCINE ADJUVANTS FOR DISEASES ASSOCIATED WITH INFECTIOUS PATHOGENS OR TOXINS
Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases... |
|
|
US20110311589 |
COMPOSITIONS AND DOSAGE REGIMES COMPRISING A CLOSTRIDIAL VACCINE AND LEVAMISOLE
A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes... |
|
|
US20120014993 |
CLOSTRIDIUM TAENIOSPORUM SPORES AND SPORE APPENDAGES AS SURFACE DISPLAY HOSTS, DRUG DELIVERY DEVICES, AND NANOBIOTECHNOLOGICAL STRUCTURES
The present disclosure relates to spore surface display compositions comprising a spore having at least one nucleic acid sequence encoding for at least one polypeptide and operable to express the... |
|
|
US20130315959 |
COMPOUNDS
The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells... |
|
|
US20140271718 |
NOVEL TYPE 1 DIABETES VACCINES, AND METHODS OF USE
The subject invention provides compositions for alleviating type 1 diabetes (T1D). In preferred embodiments, the compositions comprise an effective amount of one or more antigen presenting cells... |
|
|
US20130344104 |
OLIGOSACCHARIDES AND OLIGOSACCHARIDE-PROTEIN CONJUGATES DERIVED FROM CLOSTRIDIUM DIFFICILE POLYSACCHARIDE PS-II, METHODS OF SYNTHESIS AND USES THEREOF, IN PARTICULAR AS A VACCINE
The present invention provides an oligosaccharide-protein conjugate comprising an oligosaccharide, in particular synthetic oligosaccharide, derived from the repeating unit of the Clostridium... |
|
|
US20150140034 |
OIL-BASED ADJUVANTS
The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists,... |
|
|
US20120276132 |
Atoxic recombinant holotoxins of Clostridium difficile as immunogens
Atoxic Clostridium difficile toxin proteins were expressed in an endotoxin-free Bacillus system top develop a vaccine to reduce incidence and severity of C. difficile infection (CDI). Immunogens... |
|
|
US20130129783 |
USE OF BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS
Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and... |
|
|
US20150153330 |
sAPP-alpha as a Biomarker for Prediction of Inflammatory and Autoimmune-Related Disorders
The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related... |
|
|
US20100266534 |
Human Lymphocyte Vaccine Adjuvant
The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of... |
|
|
US20110268765 |
Injectable Botulinum Toxin Formulations
This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable... |
|
|
US20140112951 |
Vaccine and drug delivery by topical application of vectors and vector extracts
Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of... |
|
|
US20150165020 |
MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS
Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been... |
|
|
US20110182847 |
USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a... |
|
|
US20100330125 |
NOVEL POLYSACCHARIDE IMMUNOGENS FROM CLOSTRIDIUM DIFFICILE
The application relates to Clostridium difficile cell surface polysaccharides, compositions comprising Clostridium difficile cell surface polysaccharides, and includes kits, methods and uses thereof. |
|
|
US20150165016 |
POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE
The invention relates, in part, to the use of compositions of poly N-acetylated glucosamine (PNAG) and antibodies specific to PNAG in the prevention and treatment of infections by certain... |
|
|
US20140294894 |
TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to... |
|
|
US20110142881 |
TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to... |
|
|
US20100062025 |
Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine
The present invention relates to the use of a vaccine comprising Clostridium perfringens type C bacterium for protecting swine against Clostridium perfringens type A infection. |
|
|
US20150143557 |
COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells... |
|
|
US20130149339 |
COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells... |
|
|
US20110135679 |
COMPOSITIONS FOR INDUCING IMMUNE RESPONSES
The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and... |
|
|
US20140314813 |
CLOSTRIDIUM DIFFICILE LIPOTEICHOIC ACID AND USES THEREOF
A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C... |
|
|
US20090214537 |
Serum Resistance Factors of Gram Positive Bacteria
A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection. |
|
|
US20110150931 |
RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS
Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at... |
|
|
US20090136623 |
GROWTH INHIBITORY COMPOSITION AGAINST PATHOGENIC BACTERIA OF MEAT BASED FOOD STUFF COMPRISING IGY
The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12... |
|
|
US20140037716 |
IMMUNOGENIC COMPOSITION FOR IMMUNE SYSTEM MODULATION AND USE THEREOF, METHOD FOR TREATING AND PREVENTING DISEASES, METHOD FOR INDUCING CELL REGENERATION AND METHOD FOR RESTORING IMMUNE RESPONSE
The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with... |
|
|
US20100255022 |
VACCINE AGAINST CLOSTRIDIUM PERFRINGENS
There is provided a vaccine for controlling Clostridium perfringens in animals, and particularly necrotic enteritis in poultry. The vaccine may comprise a C. perfringens antigenic polypeptide or... |
|
|
US20080213316 |
Destruction of spores through glycoconjugate enhanced phagocytosis
Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method... |
|
|
US20070298093 |
Synergistic Liposomal Adjuvants
The present invention relates to liposome, mixtures or liposomes and liposomal compositions comprising at least two different adjuvants and a therapeutic agent, their production and use for the... |
|
|
US20100247573 |
Stabilization of Vaccines by Lyophilization
This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions. |
|
|
US20100215679 |
METHODS AND COMPOSITIONS FOR TREATING TULAREMIA
The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals,... |
|
|
US20090110699 |
Antigen-Adjuvant Compositions and Methods
Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions,... |
|
|
US20140127263 |
AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS
The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer... |
|
|
US20100285064 |
ADJUVANT COMPOSITION FOR VACCINE
The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant. |
|
|
US20100021546 |
CONTROLLED-RELEASE IMMUNOGENIC FORMULATIONS TO MODULATE IMMUNE RESPONSE
Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms... |
|
|
US20100266632 |
VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR
An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1),... |
|
|
US20100158952 |
MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES
The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive... |
|
|
US20110104061 |
TREATMENT OF RENAL HYPERTENSION OR CAROTID SINUS SYNDROME WITH ADVENTITIAL PHARMACEUTICAL SYMPATHETIC DENERVATION OR NEUROMODULATION
Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a... |
|
|
US20100119554 |
TRANSPLANTS
The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell,... |
|
|
US20090297559 |
USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS
The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used... |
|
|
US20070286874 |
RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE
The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the... |
|
|
US20100291131 |
CLOSTRIDIAL TOXIN NETB
The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods... |